Characterisation of ant-1 as an inhibitor of myostatin activity.
Ant-1 is a mimetic peptide of the mature C-terminal region of Myostatin. It has previously been demonstrated to have Myostatin antagonistic activity as proven by increasing satellite cell activation and macrophage infiltration during skeletal muscle regeneration. Furthermore, Ant-1 also increased my...
Saved in:
Main Author: | |
---|---|
Other Authors: | |
Format: | Final Year Project |
Language: | English |
Published: |
2011
|
Subjects: | |
Online Access: | http://hdl.handle.net/10356/45741 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-45741 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-457412023-02-28T17:59:37Z Characterisation of ant-1 as an inhibitor of myostatin activity. Irfana Begum Ikbal. Ravi Kambadur School of Biological Sciences DRNTU::Science::Biological sciences::Biochemistry Ant-1 is a mimetic peptide of the mature C-terminal region of Myostatin. It has previously been demonstrated to have Myostatin antagonistic activity as proven by increasing satellite cell activation and macrophage infiltration during skeletal muscle regeneration. Furthermore, Ant-1 also increased myogenesis in aged mice. Here, we have attempted to further characterize Ant-1 as an inhibitor of Myostatin. Biacore experiments showed that Ant-1 binds strongly to ActRIIB with an affinity of 5.34nM. Therefore, Ant-1 may potentially act as a competitive inhibitor of Myostatin by binding to ActRIIB, which is a predominant receptor to Myostatin. Moreover, we also found that Ant- 1 treatment reduced Smad3 phosphorylation, thereby reducing Smad3 transactivation activity in a promoter-reporter assay. Consistent with this, we found that Ant-1 increased the proliferation rate of myoblasts and in differentiation as confirmed by increased expression of differentiation markers. Moreover, a short-term treatment of Ant-1 enhanced insulin sensitivity in young wild type mice similar to that seen in Myostatin-null mice. Collectively, we propose that Ant-1 is an inhibitor of Myostatin activity and can be further developed as a drug to treat diseases that are promoted by Myostatin. Bachelor of Science in Biological Sciences 2011-06-16T08:42:44Z 2011-06-16T08:42:44Z 2011 2011 Final Year Project (FYP) http://hdl.handle.net/10356/45741 en Nanyang Technological University 29 p. application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
DRNTU::Science::Biological sciences::Biochemistry |
spellingShingle |
DRNTU::Science::Biological sciences::Biochemistry Irfana Begum Ikbal. Characterisation of ant-1 as an inhibitor of myostatin activity. |
description |
Ant-1 is a mimetic peptide of the mature C-terminal region of Myostatin. It has previously been demonstrated to have Myostatin antagonistic activity as proven by increasing satellite cell activation and macrophage infiltration during skeletal muscle regeneration. Furthermore, Ant-1 also increased myogenesis in aged mice.
Here, we have attempted to further characterize Ant-1 as an inhibitor of Myostatin. Biacore experiments showed that Ant-1 binds strongly to ActRIIB with an affinity of 5.34nM. Therefore, Ant-1 may potentially act as a competitive inhibitor of Myostatin by binding to ActRIIB, which is a predominant receptor to Myostatin. Moreover, we also found that Ant- 1 treatment reduced Smad3 phosphorylation, thereby reducing Smad3 transactivation activity in a promoter-reporter assay. Consistent with this, we found that Ant-1 increased the proliferation rate of myoblasts and in differentiation as confirmed by increased expression of differentiation markers. Moreover, a short-term treatment of Ant-1 enhanced insulin sensitivity in young wild type mice similar to that seen in Myostatin-null mice.
Collectively, we propose that Ant-1 is an inhibitor of Myostatin activity and can be further developed as a drug to treat diseases that are promoted by Myostatin. |
author2 |
Ravi Kambadur |
author_facet |
Ravi Kambadur Irfana Begum Ikbal. |
format |
Final Year Project |
author |
Irfana Begum Ikbal. |
author_sort |
Irfana Begum Ikbal. |
title |
Characterisation of ant-1 as an inhibitor of myostatin activity. |
title_short |
Characterisation of ant-1 as an inhibitor of myostatin activity. |
title_full |
Characterisation of ant-1 as an inhibitor of myostatin activity. |
title_fullStr |
Characterisation of ant-1 as an inhibitor of myostatin activity. |
title_full_unstemmed |
Characterisation of ant-1 as an inhibitor of myostatin activity. |
title_sort |
characterisation of ant-1 as an inhibitor of myostatin activity. |
publishDate |
2011 |
url |
http://hdl.handle.net/10356/45741 |
_version_ |
1759856874076766208 |